Evidence map›Paper›PMID 37091071›Full record

ArticleHarvard data science review2022

An R Shiny App for a Chronic Lower Back Pain Study, Personalized N-of-1 Trial.

Thevaa Chandereng

Abstract read
In one paragraph

Article in Harvard data science review, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. N-of-1 trials: The epitome of personalized medicine?Journal of clinical and translational science · 2023
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Thevaa ChanderengMailman School of Public Health, Columbia University, New York, NY, USA.

Funding

Re-engineering Precision Therapeutics Through N-of-1 TrialsR01LM012836 · NLM · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI DAVIDSON, KARINA W. · 2017 to 2023
$7.6M
Roybal Center for Personalized Trials: Physical Activity Promotion to Foster Healthy AgingP30AG063786 · NIA · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI Karina W. Davidson · 2020 to 2026
$6.7M
NIA NIH HHS P30 AG063786NLM NIH HHS R01 LM012836
6 · The paper itself

Abstract

The call for personalized medicine highlights the need for personalized (N-of-1) trials to find what treatment works best for individual patients. Conventional (between-subject) randomized controlled trials (RCT) yield effects for the 'average patient,' but a personalized trial administers all treatments within-subject, so benefits or harms to the individual patient can be identified. The design and analysis of personalized trials involve different strategies from the conventional RCT. These include how to adjust for any carryover effects from one intervention to another, how to handle missing data, and how to provide patients with insight into their data. In addition, a comprehensible report about trial results should be created for each patient and their clinician to facilitate their decision-making. This article describes strategies to address these design and analytic issues, and introduces an R shiny app to facilitate their solution, to explain the use of each of the design and statistical strategies. To illustrate, we also provide a concrete example of a personalized trial series designed to increase activity (i.e., walking steps) in patients with chronic lower back pain (CLBP).

Indexed as

computing platformsfitbit dataimputationpersonalized medicine

Identifiers

PMID37091071
PMCPMC10121210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.